Advanced Asset Management Advisors Inc acquired a new stake in Eli Lilly And Co (NYSE:LLY) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 3,266 shares of the company’s stock, valued at approximately $378,000.
Several other hedge funds also recently added to or reduced their stakes in LLY. Becker Capital Management Inc. grew its position in Eli Lilly And Co by 6.2% during the 4th quarter. Becker Capital Management Inc. now owns 2,221 shares of the company’s stock worth $257,000 after acquiring an additional 129 shares during the last quarter. Balasa Dinverno & Foltz LLC grew its position in Eli Lilly And Co by 63.3% during the 4th quarter. Balasa Dinverno & Foltz LLC now owns 5,925 shares of the company’s stock worth $686,000 after acquiring an additional 2,296 shares during the last quarter. Taylor Hoffman Wealth Management grew its position in Eli Lilly And Co by 58.3% during the 4th quarter. Taylor Hoffman Wealth Management now owns 1,629 shares of the company’s stock worth $187,000 after acquiring an additional 600 shares during the last quarter. IPG Investment Advisors LLC bought a new stake in Eli Lilly And Co during the 4th quarter worth approximately $262,000. Finally, Partnervest Advisory Services LLC grew its position in Eli Lilly And Co by 1.4% during the 4th quarter. Partnervest Advisory Services LLC now owns 6,787 shares of the company’s stock worth $785,000 after acquiring an additional 96 shares during the last quarter. Institutional investors own 80.84% of the company’s stock.
NYSE:LLY opened at $119.65 on Thursday. Eli Lilly And Co has a 52-week low of $74.51 and a 52-week high of $121.84. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.53 and a current ratio of 1.91. The firm has a market cap of $125.67 billion, a price-to-earnings ratio of 21.56, a PEG ratio of 1.91 and a beta of 0.37.
Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 6th. The company reported $1.33 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.36 by ($0.03). Eli Lilly And Co had a return on equity of 42.55% and a net margin of 13.16%. The firm had revenue of $6.44 billion for the quarter, compared to analyst estimates of $6.28 billion. During the same period in the prior year, the company posted $1.14 EPS. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, analysts expect that Eli Lilly And Co will post 5.6 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Friday, February 15th will be paid a $0.645 dividend. The ex-dividend date is Thursday, February 14th. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.16%. This is an increase from Eli Lilly And Co’s previous quarterly dividend of $0.56. Eli Lilly And Co’s dividend payout ratio is 40.54%.
A number of equities research analysts recently commented on LLY shares. UBS Group decreased their price target on Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating on the stock in a research report on Friday, February 8th. TheStreet upgraded Eli Lilly And Co from a “c+” rating to a “b+” rating in a research report on Tuesday, November 6th. Cantor Fitzgerald restated a “buy” rating and set a $128.00 price target on shares of Eli Lilly And Co in a research report on Wednesday, October 17th. Zacks Investment Research upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $128.00 price target on the stock in a research report on Wednesday, November 28th. Finally, ValuEngine upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating in a research report on Monday, November 12th. Eleven investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $111.41.
In other news, SVP Alfonso G. Zulueta sold 4,000 shares of the stock in a transaction on Thursday, January 31st. The stock was sold at an average price of $120.00, for a total value of $480,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the stock in a transaction on Friday, November 16th. The shares were sold at an average price of $113.74, for a total value of $22,748,000.00. Following the completion of the transaction, the insider now directly owns 118,600,804 shares in the company, valued at approximately $13,489,655,446.96. The disclosure for this sale can be found here. In the last three months, insiders sold 817,843 shares of company stock worth $94,595,335. 0.11% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: “Advanced Asset Management Advisors Inc Takes Position in Eli Lilly And Co (LLY)” was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://transcriptdaily.com/2019/02/14/advanced-asset-management-advisors-inc-takes-position-in-eli-lilly-and-co-lly.html.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Story: Institutional Investors
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.